Am Fam Physician. 1998 Feb 1;57(3):426-427.
to the editor: King and Pippin1 hesitate to make doxycycline (Vibramycin) their first choice for outpatient treatment of community-acquired pneumonia in spite of their praise for its low cost and easy dosing schedule. Their only stated reason for reservation is that Streptococcus pneumoniae “resistance to this agent is increasing.”
The authors' two references on this point offer no evidence for their assertion. One is a primary research paper which does not mention doxycycline.2 The other is a review article by Mandell3 which contains a statement similar to the one made by Drs. King and Pippin. The reference given for this claim in the Mandell article is a 1973 paper by Gopalakrishna and Lerner.4 These authors serially tested for tetracycline resistance in one hospital over the course of 31 months; they did not report similar testing for doxycycline. The data presented do not allow the reader to determine the prevalence of doxycycline resistance at any point in time, let alone ascertain that the rate of resistance had increased during the study.
Perhaps Drs. King and Pippin have made the common error of assuming that tetracycline resistance, which is indeed common for S. pneumoniae, implies doxycycline resistance as well. This is not true.5
Doxycycline is consistently active against all common typical and atypical bacterial causes of pneumonia, is inexpensive, offers twice-daily dosing, has a favorable side-effect profile, and achieves unusually high penetration into lung tissue and especially into alveolar macrophages.5,6 Doxycycline is, in short, a nearly ideal antibiotic for initial outpatient treatment of community-acquired pneumonia in adults.
1. King DE, Pippin HJ Jr. Community-acquired pneumonia in adults: initial antibiotic therapy. Am Fam Physician. 1997;56:544–50.
2. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34:2075–80.
3. Mandell LA. Antibiotics for pneumonia therapy. Med Clin North Am. 1994;78:997–1014.
4. Gopalakrishna KV, Lerner PI. Tetracycline-resistant pneumococci: increasing incidence and cross resistance to newer tetracyclines. Am Rev Respir Dis. 1973;108:1007–10.
5. Shea KW, Cunha BA, Ueno Y, Abumustafa F, Qadri SM. Doxycycline activity against Streptococcus pneumoniae [Letter]. Chest. 1995;108:1775–6.
6. Cunha BA. Community-acquired pneumonia. Cost-effective antimicrobial therapy [Published erratum appears in Postgrad Med. 1996;99(5):51]. Postgrad Med. 1996;991109–22.
in reply: We wish to apologize to the readers of American Family Physician for incorrectly referencing our comments concerning doxycycline resistance. We intended to reference items 13 and 19 rather than items 13 and 16.
Dr. Woolley wonders why we hesitate to make doxycycline our first choice for out-patient treatment of community-acquired pneumonia. The article we intended to cite1 indicates that doxycycline resistance is a class effect, since both doxycycline and tetracycline resistance are plasmid-mediated. The article referenced by Dr. Woolley2 is a letter to the editor pointing out in vitro data which demonstrate 21 percent intermediate and full resistance to tetracycline (for S. pneumoniae) and 16 percent intermediate and full resistance to doxycycline. In vivo clinical experience with doxycycline in pneumonia is very limited. In contrast, the American Thoracic Society guidelines show erythromycin (Ery-Tab) to be a very cost-effective choice.3 In addition, erythromycin has more reliable activity against Legionella pneumophila than doxycycline. Further clinical in vivo research with doxycycline may uphold Dr. Woolley's position; until then, we feel that erythromycin is still the first choice for initial antibiotic therapy of uncomplicated community-acquired pneumonia.
1. Smilack JD, Wilson WR, Cockerill FR III. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin Proc. 1991;66:1270–80.
2. Shea KW, Cunha BA, Ueno Y, Abumustafa F, Qadri SM. Doxycycline activity against Streptococcus pneumoniae [Letter]. Chest. 1995;108:1775–6.
3. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA. 1997;278:32–9.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions